Effects of a 6-month course of tamsulosin for chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized trial

Nickel JC, Downey J, Hunter D, Clark J (2001) Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol 165:842–845

Cornel EB, van Haarst EP, Schaarsbergc RW, Geels J (2005) The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III. Eur Urol 47:607–611

Ishigooka M, Zermann DH, Doggweiler R, Schmidt RA (2000) Similarity of distributions of spinal c-Fos and plasma extravasation after acute chemical irritation of the bladder and the prostate. J Urol 164:1751–1756

Nickel JC (2006) Alpha-blockers for the treatment of prostatitis-like syndromes. Rev Urol 8(suppl 4):S26–S34

Tugcu V, Tasci AI, Fazlioglu A, Gurbuz G, Ozbek E, Sahin S, Kurtulus F, Cek M (2006) A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 51(4):1113–1118

Nickel JC, Krieger JN, McNaughton-Collins M, Anderson RU, Pontari M et al (2008) Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. N Engl J Med 359(25):2663–2673

Nickel JC, Narayan P, McKay J, Doyle C (2004) Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 171(4):1594–1597

Cheah PY, Liong ML, Yuen KH et al (2004) Initial, long term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome. Urology 64:881–886

Litwin MS, McNaughton-Collins M, Fowler FJ Jr et al (1999) The National Institutes of health chronic prostatitis symptom index (NIH-CPSI): development and validation of a new outcomes measure. J Urol 162:369–375

Propert KJ, Litwin MS, Wang Y et al (2006) Responsiveness of the national institutes of health chronic prostatitis symptom index (NIH-CPSI). Qual Life Res 15:299–305

Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A (1997) The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830

Duclos AJ, Lee CT, Shoskes DA (2007) Current treatment options in the management of chronic prostatitis. Ther Clin Risk Manag 3:507–512

Liao LM, Shi BY, Liang CQ (1999) Ambulatory urodynamic monitoring of external urethral sphincter behavior in chronic prostatitis patients. Asian Journal of Andrology 1(4):215–217

Andersson KE, Gratzke C (2007) Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 4:368–378

Ishigooka M, Nakada T, Hashimoto T et al (2002) Spinal substance P immunoreactivity is enhanced by acute chemical stimulation of the rat prostate. Urology 59(1):139–144

Geppetti P, Nassini R, Materazzi S, Benemei S (2008) The concept of neurogenic inflammation. BJU Int 101(Suppl):2–6

Nickel JC, Narayan P, McKay J, Doyle C (2004) Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial. J Urol 171:1594–1597

Mehik A, Alas P, Nickel JC, Sarpola A, Helstrom PJ (2003) Alfuzosin treatment for chronicprostatitis/chronic pelvic pain syndrome:a prospective, randomized, double-blind, placebo-controlled, pilot study. Urology 62:425–429

Chen Y, Song B, Jin XY, Xiong EQ, Zhang JH (2005) Possible mechanism of referred pain in the perineum and pelvis associated with the prostate in rats. J Urol 174:2405–2408

Li NC, Chen S, Yang XH, Du LD, Yang JY, Na YQ (2003) Efficacy of low-dose tamsulosin in chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Invest 23(12):781–787